Andrew Robert Marks

This inventor holds 11 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Columbia University. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Robert Marks. Retrieved from https://idiyas.com/inventor/andrew-robert-marks

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 7)

% Patents Active = 45.5

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.1

ph-index = 5

Forward Citations = 41(Granted Patents)

Location History:

Larchmont, NY (US) (2002 - 2014)
Larchmonth, NY (US) (2021)

Company Filing History:

11 out of 2,552

Columbia University

patents

Years Active: 2002-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10925976 - Smooth muscle specific inhibition for anti-restenotic therapy (2021-02-23),

2. 8710045 - Agents for preventing and treating disorders involving modulation of the ryanodine receptors (2014-04-29),

3. 8022058 - Agents for preventing and treating disorders involving modulation of the RyR receptors (2011-09-20),

4. 7879840 - Agents for preventing and treating disorders involving modulation of the RyR receptors (2011-02-01),

5. 7718644 - Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof (2010-05-18),

6. 7662178 - C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis (2010-02-16),

7. 7544678 - Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) (2009-06-09),

8. 7393652 - Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) (2008-07-01),

9. 7364586 - C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis (2008-04-29),

10. 7312044 - Type 1 ryanodine receptor-based methods (2007-12-25),

11. 6489125 - Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor (2002-12-03),

Title: The Innovations of Andrew Robert Marks

Introduction

Andrew Robert Marks is a prominent inventor based in Larchmont, NY (US). He has made significant contributions to the field of medical science, particularly in cardiovascular therapies. With a total of 11 patents to his name, Marks has demonstrated a commitment to advancing healthcare through innovative solutions.

Latest Patents

Among his latest patents is the invention titled "Smooth muscle specific inhibition for anti-restenotic therapy." This invention focuses on incorporating target sequences of microRNAs into the 3'UTR region of a gene of interest within nucleic acid vectors. It also includes an expression system comprising such vectors, a pharmaceutical composition utilizing these vectors, and methods for treating or preventing cardiovascular disease. Another notable patent is "Agents for preventing and treating disorders involving modulation of the ryanodine receptors." This invention provides compounds of Formula I, along with their salts, hydrates, solvates, complexes, and prodrugs. It further outlines methods for synthesizing these compounds and pharmaceutical compositions for treating disorders associated with RyR receptors that regulate calcium channel functioning in cells.

Career Highlights

Andrew Robert Marks is affiliated with Columbia University, where he continues to engage in groundbreaking research. His work has not only contributed to the academic community but has also had a profound impact on practical applications in medicine.

Collaborations

Marks has collaborated with esteemed colleagues, including Donald W. Landry and Shixian Deng. These partnerships have fostered an environment of innovation and have led to the development of significant medical advancements.

Conclusion

Andrew Robert Marks exemplifies the spirit of innovation in the medical field through his numerous patents and collaborations. His work continues to pave the way for new therapies that can improve patient outcomes in cardiovascular health.

Profile summary based on public USPTO records.